D-dimer testing to determine the duration of anticoagulant therapy

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 5, 2007, Pages 393-397

  Palareti, Gualtiero ^a   Cosmi, Benilde ^a   Legnani, Cristina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anticoagulation duration; D dimer; Recurrence; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; D DIMER; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; CANCER; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROSPECTIVE STUDY; RECURRENT DISEASE; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PREDICTIVE VALUE OF TESTS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS;

EID: 34748902943     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282058b94     Document Type: Review

References (33)

1. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
2. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. Arch Intern Med 2000; 160:761-768.
3. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332:1661-1665.
4. DeStefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-806.
5. Lindmarker P, Schulman S, StenLinder M, et al. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81:684-689.
6. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997.
7. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457-462.
8. Legnani C, Cosmi B, Cini M, et al. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004; 124:504-510.
9. Weltermann A, Eichinger S, Bialonczyk C, et al. The risk of recurrent venous thromboembolismamong patients with high factor IX levels. J Thromb Haemost 2003; 1:28-32.
10. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362:523-526.
11. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108:313-318.
12. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia - A systematic review. Arch Intern Med 2006; 166:729-736. An interesting review of studies evaluating the role of FV Leiden and the G20210A prothrombin mutation in recurrent venous thromboembolism.
13. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-398.
14. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84:805-810.
15. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484-3488.
16. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103:2453-2460.
17. Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99:3102-3110.
18. Cosmi B, Palareti G. Extended treatment for venous thromboembolism: how long is long enough? Curr Hematol Rep 2004; 3:375-381.
19. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345:165-169.
20. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003; 139:19-25.
21. Palareti G, Cosmi B, Legnani C. Diagnosis of deep vein thrombosis. Semin Thromb Hemost 2006; 32:659-672.
22. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants - a prospective study. Thromb Haemost 1994; 72:222-226.
23. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87:7-12.
24. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003; 290:1071-1074.
25. Shrivastava S, Ridker PM, Glynn RJ, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 2006; 4:1208-1214. This paper describes the prognostic value of D-dimer for recurrent VTE in a posthoc analysis of the double-blind randomized PREVENT (Prevention of Recurrent Venous Thromboembolism) trial.
26. Cosmi B, Legnani C, Cini M, et al. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost 2005; 94:969-974.
27. Cosmi B, Legnani C, Cini M, et al. The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica 2005; 90:713-715.
28. Kuruvilla J, Wells PS, Morrow B, et al. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost 2003; 89:284-287.
29. Kevorkian JP, Halimi C, Segrestaa JM, et al. Monitoring of patients with deep-vein thrombosis during and after anticoagulation with d-dimer. Lancet 1998; 351:571-572.
30. Fattorini A, Crippa L, Vigano' D'Angelo S, et al. Risk of deep vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation. Thromb Haemost 2002; 88:162-163.
31. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355:1780-1789. The first randomized clinical trial evaluating the role of D-dimer to establish the duration of anticoagulation.
32. Cini M, Legnani C, Cavallaroni K, et al. A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. J Thromb Haemost 2003; 1:2681-2683.
33. Hager K, Platt D. Fibrin degeneration product concentrations (d-dimers) in the course of ageing. Gerontology 1995; 41:159-165.